Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

PURPOSE: To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide (TMZ) in patients with recurrent high-grade astrocytoma. EXPERIMENTAL DESIGN: This two-stage phase 1 trial determined the maximum tolerated dose (MTD) of zotiraciclib combined with...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Wu, Jing, Yuan, Ying, Priel, Debra Long, Fink, Danielle, Peer, Cody J., Sissung, Tristan, Su, Yu-Ting, Pang, Ying, Yu, Guangyang, Butler, Madison K., Mendoza, Tito R., Vera, Elizabeth, Ahmad, Salman, Bryla, Christine, Lindsley, Matthew, Grajkowska, Ewa, Mentges, Kelly, Boris, Lisa, Antony, Ramya, Garren, Nancy, Siegel, Christine, Lollo, Nicole, Cordova, Christine, Aboud, Orwa, Theeler, Brett, Burton, Eric, Penas-Prado, Marta, Leeper, Heather, Gonzales, Javier, Armstrong, Terri S., Calvo, Katherine R., Figg, William D., Kuhns, Douglas B., Gallin, John I., Gilbert, Mark R.
Формат: Artigo
Язык:Inglês
Опубликовано: 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8197750/
https://ncbi.nlm.nih.gov/pubmed/33785481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4730
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы